Paolo Tarantino: Important update of the ABC trials

Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

“Important update of the ABC trials.

With 6.9y of follow up, adjuvant AC-T had a small RFI benefit over TC, restricted to triple-negative tumors.

No OS benefit by adding anthracyclines, but a major increase in leukemias (7 vs 1) & non-BC deaths (62 vs 34).

https://ascopubs.org/doi/10.1200/JCO.23.01428 “

Source: Paolo Tarantino / X